JAMP LURASIDONE 120 MG
LURASIDONE HYDROCHLORIDE : 120 MG · DIN 02516470 · JAMP PHARMA CORPORATION
Health Canada status: MARKETED
What is JAMP LURASIDONE?
JAMP LURASIDONE 120 MG contains LURASIDONE HYDROCHLORIDE : 120 MG. It is listed in the Health Canada Drug Product Database under DIN 02516470, held by JAMP PHARMA CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 02-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JAMP LURASIDONE used for?
Management of schizophrenia in adults and adolescents (15-17). Monotherapy or adjunctive therapy for depressive episodes associated with bipolar I disorder in adults and adolescents (13-17).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02516470 |
|---|---|
| Brand name | JAMP LURASIDONE |
| Generic / active ingredient | LURASIDONE HYDROCHLORIDE : 120 MG |
| Manufacturer | JAMP PHARMA CORPORATION |
| Strength | 120 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AE05 LURASIDONE |
| AHFS class | 28:16.08.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 02-Sep-2022 |
| Original market date | 2022-09-02 00:00:00 |
How is it administered?
Administer orally once daily with food (at least 350 calories). Dose ranges from 20 mg to 160 mg depending on indication and age. Adjust for renal/hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in provided text (refers to Part I, Section 10). Typically 15-30°C.
How is it supplied?
Not explicitly detailed in provided text (refers to Part III/Composition section). Typically bottles or blisters.
Contraindications
Hypersensitivity to lurasidone or components; co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).
Warnings and precautions
Increased mortality in elderly patients with dementia. Risk of Neuroleptic Malignant Syndrome, Tardive Dyskinesia, orthostatic hypotension, QT prolongation, and metabolic changes.
What can be used instead?
Other Canadian products sharing ATC code N05AE05 LURASIDONE. 33 of 40 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-LURASIDONE | 120 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02514036 |
| AURO-LURASIDONE | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02513986 |
| AURO-LURASIDONE | 40 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02513994 |
| AURO-LURASIDONE | 60 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02514001 |
| AURO-LURASIDONE | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02514028 |
| JAMP LURASIDONE | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02516438 |
| JAMP LURASIDONE | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02516446 |
| JAMP LURASIDONE | 60 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02516454 |
| JAMP LURASIDONE | 80 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02516462 |
| LURASIDONE | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02548585 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.